{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:31:32Z","timestamp":1793406692404,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41429-026-00927-x","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:25:14Z","timestamp":1779773114000},"page":"425-436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aztreonam\u2013avibactam at the frontline: A dual-agent approach to metallo-\u03b2-lactamase resistance"],"prefix":"10.1038","volume":"79","author":[{"given":"Priti","family":"Mohite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3662-4635","authenticated-orcid":false,"given":"Sanjay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"927_CR1","doi-asserted-by":"publisher","first-page":"e00397","DOI":"10.1128\/AAC.00397-20","volume":"64","author":"SE Boyd","year":"2020","unstructured":"Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-\u03b2-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. Antimicrob Agents Chemother. 2020;64:e00397\u201320.","journal-title":"Antimicrob Agents Chemother"},{"key":"927_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1749-6632.2012.06796.x","volume":"1277","author":"T Palzkill","year":"2013","unstructured":"Palzkill T. Metallo-\u03b2-lactamase structure and function. Ann N Y Acad Sci. 2013;1277:91\u2013104.","journal-title":"Ann N Y Acad Sci"},{"key":"927_CR3","doi-asserted-by":"publisher","first-page":"02817","DOI":"10.3389\/fmicb.2019.02817","volume":"10","author":"RE Weber","year":"2019","unstructured":"Weber RE, et al. IS26-Mediated Transfer of blaNDM\u20131 as the Main Route of Resistance Transmission During a Polyclonal, Multispecies Outbreak in a German Hospital. Front Microbiol. 2019;10:02817.","journal-title":"Front Microbiol"},{"key":"927_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jgar.2018.01.026","volume":"13","author":"SM Liew","year":"2018","unstructured":"Liew SM, Rajasekaram G, Puthucheary SD, Chua KH. Detection of VIM-2-, IMP-1- and NDM-1-producing multidrug-resistant Pseudomonas aeruginosa in Malaysia. J Glob Antimicrob Resist. 2018;13:271\u20133.","journal-title":"J Glob Antimicrob Resist"},{"key":"927_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1089\/mdr.2024.0059","volume":"30","author":"W Ma","year":"2024","unstructured":"Ma W, et al. Characterization of the Chromosomally Located Metallo- \u03b2 -Lactamase Genes bla IMP-45 and bla VIM-2 in a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate. Microb Drug Resist. 2024;30:422\u201331.","journal-title":"Microb Drug Resist"},{"key":"927_CR6","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/cid\/ciad725","volume":"78","author":"M Falcone","year":"2024","unstructured":"Falcone M, et al. Clinical Features and Outcomes of Infections Caused by Metallo-\u03b2-Lactamase\u2013Producing Enterobacterales: A 3-Year Prospective Study From an Endemic Area. Clin Infect Dis. 2024;78:1111\u20139.","journal-title":"Clin Infect Dis"},{"key":"927_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1473-3099(11)70059-7","volume":"11","author":"TR Walsh","year":"2011","unstructured":"Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011;11:355\u201362.","journal-title":"Lancet Infect Dis"},{"key":"927_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12866-017-1012-8","volume":"17","author":"AU Khan","year":"2017","unstructured":"Khan AU, Maryam L, Zarrilli R. Structure, Genetics and Worldwide Spread of New Delhi Metallo-\u03b2-lactamase (NDM): a threat to public health. BMC Microbiol. 2017;17:101.","journal-title":"BMC Microbiol"},{"key":"927_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/jacm.jacm_21_22","volume":"24","author":"S Joshi","year":"2022","unstructured":"Joshi S. Beta-lactam beta-lactamase inhibitors. J Acad Clin Microbiol. 2022;24:63\u201370.","journal-title":"J Acad Clin Microbiol"},{"key":"927_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacother J Hum Pharmacol Drug Ther. 2019;39:10\u201339.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"927_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106487","volume":"59","author":"G Dimopoulos","year":"2022","unstructured":"Dimopoulos G, et al. Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia. Int J Antimicrob Agents. 2022;59:106487.","journal-title":"Int J Antimicrob Agents"},{"key":"927_CR12","doi-asserted-by":"publisher","first-page":"1178547","DOI":"10.3389\/fcimb.2023.1178547","volume":"13","author":"V Mattioni Marchetti","year":"2023","unstructured":"Mattioni Marchetti V, Hrabak J, Bitar I. Fosfomycin resistance mechanisms in Enterobacterales: an increasing threat. Front Cell Infect Microbiol. 2023;13:1178547.","journal-title":"Front Cell Infect Microbiol"},{"key":"927_CR13","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s40265-024-02102-8","volume":"84","author":"C Hidalgo-Tenorio","year":"2024","unstructured":"Hidalgo-Tenorio C, et al. The Challenge of Treating Infections Caused by Metallo-\u03b2-Lactamase\u2013Producing Gram-Negative Bacteria: A Narrative Review. Drugs. 2024;84:1519\u201339.","journal-title":"Drugs"},{"key":"927_CR14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/antibiotics13090874","volume":"13","author":"C Kirkegaard-Biosca","year":"2024","unstructured":"Kirkegaard-Biosca C, et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. Antibiotics. 2024;13:874.","journal-title":"Antibiotics"},{"key":"927_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jgar.2022.06.018","volume":"30","author":"GM Rossolini","year":"2022","unstructured":"Rossolini GM, Stone G, Kantecki M, Arhin FF. In vitro activity of aztreonam\/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019. J Glob Antimicrob Resist. 2022;30:214\u201321.","journal-title":"J Glob Antimicrob Resist"},{"key":"927_CR16","doi-asserted-by":"publisher","first-page":"ofaf250","DOI":"10.1093\/ofid\/ofaf250","volume":"12","author":"KM Papp-Wallace","year":"2025","unstructured":"Papp-Wallace KM, Sader HS, Maher JM, Kimbrough JH, Castanheira M. Aztreonam-avibactam Demonstrates Potent Activity Against Carbapenem-resistant Enterobacterales Collected From US Medical Centers Over a 6-year Period (2017\u20132022). Open Forum Infect Dis. 2025;12:ofaf250.","journal-title":"Open Forum Infect Dis"},{"key":"927_CR17","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.3201\/eid2710.211265","volume":"27","author":"J Findlay","year":"2021","unstructured":"Findlay J, Poirel L, Kessler J, Kronenberg A, Nordmann P. New Delhi Metallo-\u03b2-Lactamase\u2013Producing Enterobacterales Bacteria, Switzerland, 2019\u20132020. Emerg Infect Dis. 2021;27:2628\u201337.","journal-title":"Emerg Infect Dis"},{"key":"927_CR18","doi-asserted-by":"publisher","first-page":"e41540","DOI":"10.1016\/j.heliyon.2024.e41540","volume":"11","author":"VR Flores-Vega","year":"2025","unstructured":"Flores-Vega VR, Partida-Sanchez S, Ares MA, Ortiz-Navarrete V, Rosales-Reyes R. High-risk Pseudomonas aeruginosa clones harboring \u03b2-lactamases: 2024 update. Heliyon. 2025;11:e41540.","journal-title":"Heliyon"},{"key":"927_CR19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.15537\/smj.2022.43.9.20220219","volume":"43","author":"P Saengsuwan","year":"2022","unstructured":"Saengsuwan P, Kositpantawong N, Kawila S, Patugkaro W, Romyasamit C. Prevalence of carbapenemase genes among multidrug-resistant Pseudomonas aeruginosa isolates from tertiary care centers in Southern Thailand. Saudi Med J. 2022;43:991\u20139.","journal-title":"Saudi Med J"},{"key":"927_CR20","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.3390\/microorganisms13092015","volume":"13","author":"J-R Gerges","year":"2025","unstructured":"Gerges J-R, et al. Molecular Epidemiology of Carbapenem-Resistant P. aeruginosa and Enterobacterales Isolates from Clinical Infections and Their Susceptibility to Ceftazidime\u2013Avibactam. Microorganisms. 2025;13:2015.","journal-title":"Microorganisms"},{"key":"927_CR21","doi-asserted-by":"publisher","first-page":"e0021622","DOI":"10.1128\/aac.00216-22","volume":"66","author":"SE Boyd","year":"2022","unstructured":"Boyd SE, Holmes A, Peck R, Livermore DM, Hope W. OXA-48-Like \u03b2-Lactamases: Global epidemiology, treatment options, and development pipeline. Antimicrob Agents Chemother. 2022;66:e0021622.","journal-title":"Antimicrob Agents Chemother"},{"key":"927_CR22","doi-asserted-by":"publisher","first-page":"e0292288","DOI":"10.1371\/journal.pone.0292288","volume":"18","author":"S Aghamohammad","year":"2023","unstructured":"Aghamohammad S, Khazani Asforooshani M, Malek Mohammadi Y, Sholeh M, Badmasti F. Decoding the genetic structure of conjugative plasmids in international clones of Klebsiella pneumoniae: A deep dive into blaKPC, blaNDM, blaOXA-48, and blaGES genes. PLoS ONE. 2023;18:e0292288.","journal-title":"PLoS ONE"},{"key":"927_CR23","doi-asserted-by":"publisher","first-page":"765113","DOI":"10.3389\/fmicb.2021.765113","volume":"12","author":"M Doumith","year":"2022","unstructured":"Doumith M, et al. Genomic Characterization of Carbapenem-Non-susceptible Pseudomonas aeruginosa Clinical Isolates From Saudi Arabia Revealed a Global Dissemination of GES-5-Producing ST235 and VIM-2-Producing ST233 Sub-Lineages. Front Microbiol. 2022;12:765113.","journal-title":"Front Microbiol"},{"key":"927_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/antibiotics14010063","volume":"14","author":"GV Sakalauskien\u0117","year":"2025","unstructured":"Sakalauskien\u0117 GV, Malcien\u0117 L, Stankevi\u010dius E, Radzevi\u010dien\u0117 A. Unseen Enemy: Mechanisms of Multidrug Antimicrobial Resistance in Gram-Negative ESKAPE Pathogens. Antibiotics. 2025;14:63.","journal-title":"Antibiotics"},{"key":"927_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/antibiotics11020144","volume":"11","author":"J-F Timsit","year":"2022","unstructured":"Timsit J-F, Wicky P-H, de Montmollin E. Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients. Antibiotics. 2022;11:144.","journal-title":"Antibiotics"},{"key":"927_CR26","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.cmi.2024.11.006","volume":"31","author":"G Sangiorgio","year":"2025","unstructured":"Sangiorgio G, Calvo M, Stefani S. Aztreonam and avibactam combination therapy for metallo-\u03b2-lactamase-producing gram-negative bacteria: A Narrative Review. Clin Microbiol Infect. 2025;31:971\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"927_CR27","doi-asserted-by":"publisher","first-page":"959107","DOI":"10.3389\/fmicb.2022.959107","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, et al. Drug development concerning metallo-\u03b2-lactamases in gram-negative bacteria. Front Microbiol. 2022;13:959107.","journal-title":"Front Microbiol"},{"key":"927_CR28","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s10096-023-04645-2","volume":"42","author":"MG Wise","year":"2023","unstructured":"Wise MG, Karlowsky JA, Mohamed N, Kamat S, Sahm DF. In vitro activity of aztreonam\u2013avibactam against Enterobacterales isolates collected in Latin America, Africa\/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019\u20132021. Eur J Clin Microbiol Infect Dis. 2023;42:1135\u201343.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"927_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jgar.2025.06.002","volume":"44","author":"LM Deshpande","year":"2025","unstructured":"Deshpande LM, Doyle TB, Sader HS, Castanheira M. Activity of aztreonam-avibactam and ceftazidime-avibactam against \u03b2-lactamase-producing enterobacterales Isolates from United States hospitals. J Glob Antimicrob Resist. 2025;44:103\u201310.","journal-title":"J Glob Antimicrob Resist"},{"key":"927_CR30","doi-asserted-by":"publisher","first-page":"00936","DOI":"10.3389\/fmicb.2020.00936","volume":"11","author":"H Solgi","year":"2020","unstructured":"Solgi H, et al. Molecular Epidemiology of OXA-48 and NDM-1 Producing Enterobacterales Species at a University Hospital in Tehran, Iran, Between 2015 and 2016. Front Microbiol. 2020;11:00936.","journal-title":"Front Microbiol"},{"key":"927_CR31","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.1128\/AAC.03057-14","volume":"58","author":"SD Lahiri","year":"2014","unstructured":"Lahiri SD, et al. Avibactam and Class C \u03b2-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance. Antimicrob Agents Chemother. 2014;58:5704\u201313.","journal-title":"Antimicrob Agents Chemother"},{"key":"927_CR32","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","volume":"109","author":"DE Ehmann","year":"2012","unstructured":"Ehmann DE, et al. Avibactam is a covalent, reversible, non\u2013\u03b2-lactam \u03b2-lactamase inhibitor. Proc Natl Acad Sci. 2012;109:11663\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"927_CR33","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.1128\/AAC.00897-16","volume":"60","author":"MI Abboud","year":"2016","unstructured":"Abboud MI, et al. Interaction of Avibactam with Class B Metallo-\u03b2-Lactamases. Antimicrob Agents Chemother. 2016;60:5655\u201362.","journal-title":"Antimicrob Agents Chemother"},{"key":"927_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/phar.1622","volume":"35","author":"EJ Zasowski","year":"2015","unstructured":"Zasowski EJ, Rybak JM, Rybak MJ. The \u03b2-Lactams Strike Back: Ceftazidime-Avibactam. Pharmacother J Hum Pharmacol Drug Ther. 2015;35:755\u201370.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"927_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijid.2020.05.075","volume":"97","author":"B Zhang","year":"2020","unstructured":"Zhang B, et al. In vitro activity of aztreonam\u2013avibactam against metallo-\u03b2-lactamase-producing Enterobacteriaceae\u2014A multicenter study in China. Int J Infect Dis. 2020;97:11\u201318.","journal-title":"Int J Infect Dis"},{"key":"927_CR36","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/jac\/dkx496","volume":"73","author":"E Shaw","year":"2018","unstructured":"Shaw E, et al. Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother. 2018;73:1104\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"927_CR37","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3390\/antibiotics12111591","volume":"12","author":"D Pi\u00e9rard","year":"2023","unstructured":"Pi\u00e9rard D, Hermsen ED, Kantecki M, Arhin FF. Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016\u20132020. Antibiotics. 2023;12:1591.","journal-title":"Antibiotics"},{"key":"927_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jgar.2023.12.027","volume":"36","author":"GM Rossolini","year":"2024","unstructured":"Rossolini GM, Arhin FF, Kantecki M. In vitro activity of aztreonam-avibactam and comparators against Metallo-\u03b2-Lactamase-producing Enterobacterales from ATLAS Global Surveillance Program, 2016\u20132020. J Glob Antimicrob Resist. 2024;36:123\u201331.","journal-title":"J Glob Antimicrob Resist"},{"key":"927_CR39","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/antibiotics14080762","volume":"14","author":"J Z\u00e1vora","year":"2025","unstructured":"Z\u00e1vora J, Ad\u00e1mkov\u00e1 V, Studen\u00e1 A, Kroneislov\u00e1 G. In Vitro Activity of Cefiderocol and Aztreonam\/Avibactam Against Gram-Negative Non-Fermenting Bacteria: A New Strategy Against Highly Antibiotic-Resistant Infectious Agents. Antibiotics. 2025;14:762.","journal-title":"Antibiotics"},{"key":"927_CR40","doi-asserted-by":"publisher","first-page":"e04823","DOI":"10.1128\/spectrum.00569-23","volume":"11","author":"Y-S Huang","year":"2023","unstructured":"Huang Y-S, Chen P-Y, Chou P-C, Wang J-T. In Vitro Activities and Inoculum Effects of Cefiderocol and Aztreonam-Avibactam against Metallo-\u03b2-Lactamase-Producing Enterobacteriaceae. Microbiol Spectr. 2023;11:e04823\u201322.","journal-title":"Microbiol Spectr"},{"key":"927_CR41","doi-asserted-by":"publisher","first-page":"1047109","DOI":"10.3389\/fmicb.2022.1047109","volume":"13","author":"K Ma","year":"2022","unstructured":"Ma K, Zong Z. Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids in Escherichia coli. Front Microbiol. 2022;13:1047109.","journal-title":"Front Microbiol"},{"key":"927_CR42","doi-asserted-by":"publisher","first-page":"dlae141","DOI":"10.1093\/jacamr\/dlae141","volume":"6","author":"G Haidar","year":"2024","unstructured":"Haidar G, et al. Emergence of high-level aztreonam\u2013avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline. Jac Antimicrob Resist. 2024;6:dlae141.","journal-title":"Jac Antimicrob Resist"},{"key":"927_CR43","doi-asserted-by":"publisher","first-page":"e0195024","DOI":"10.1128\/aac.01950-24","volume":"69","author":"R Xie","year":"2025","unstructured":"Xie R, Rogers H, Chow JW, Soto E, Raber SR. Population pharmacokinetic\/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients. Antimicrob Agents Chemother. 2025;69:e0195024.","journal-title":"Antimicrob Agents Chemother"},{"key":"927_CR44","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","volume":"25","author":"Y Carmeli","year":"2025","unstructured":"Carmeli Y, et al. Aztreonam\u2013avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial. Lancet Infect Dis. 2025;25:218\u201330.","journal-title":"Lancet Infect Dis"},{"key":"927_CR45","doi-asserted-by":"publisher","first-page":"dlaf131","DOI":"10.1093\/jacamr\/dlaf131","volume":"7","author":"GL Daikos","year":"2025","unstructured":"Daikos GL, et al. Aztreonam\u2013avibactam for the treatment of serious infections caused by metallo-\u03b2-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE). Jac Antimicrob Resist. 2025;7:dlaf131.","journal-title":"Jac Antimicrob Resist"},{"key":"927_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102293","volume":"65","author":"KA Budai","year":"2023","unstructured":"Budai KA, et al. Extended infusion of \u03b2-lactams significantly reduces mortality and enhances microbiological eradication in paediatric patients: a systematic review and meta-analysis. EClinicalMedicine. 2023;65:102293.","journal-title":"EClinicalMedicine"},{"key":"927_CR47","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/phar.2842","volume":"43","author":"LT Hong","year":"2023","unstructured":"Hong LT, et al. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Pharmacother J Hum Pharmacol Drug Ther. 2023;43:740\u201377.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"927_CR48","doi-asserted-by":"publisher","first-page":"e2418234","DOI":"10.1001\/jamanetworkopen.2024.18234","volume":"7","author":"SM Karaba","year":"2024","unstructured":"Karaba SM, et al. Extended-Infusion \u03b2-Lactam Therapy, Mortality, and Subsequent Antibiotic Resistance Among Hospitalized Adults With Gram-Negative Bloodstream Infections. JAMA Netw Open. 2024;7:e2418234.","journal-title":"JAMA Netw Open"},{"key":"927_CR49","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40261-023-01257-8","volume":"43","author":"C Prinz","year":"2023","unstructured":"Prinz C, et al. Feasibility of Continuous Infusion of Cefiderocol in Conjunction with the Establishment of Therapeutic Drug Monitoring in Patients with Extensively Drug-Resistant Gram-Negative Bacteria. Clin Drug Investig. 2023;43:307\u201314.","journal-title":"Clin Drug Investig"},{"key":"927_CR50","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jac\/dkz497","volume":"75","author":"OA Cornely","year":"2020","unstructured":"Cornely OA, et al. Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. J Antimicrob Chemother. 2020;75:618\u201327.","journal-title":"J Antimicrob Chemother"},{"key":"927_CR51","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00228-023-03609-x","volume":"80","author":"S Das","year":"2024","unstructured":"Das S, et al. Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation. Eur J Clin Pharmacol. 2024;80:529\u201343.","journal-title":"Eur J Clin Pharmacol"},{"key":"927_CR52","unstructured":"www.fda.gov\/medwatch And, ------------------------Dosage & Administration------------------. HIGHLIGHTS OF PRESCRIBING INFORMATION Recommended Dosage in Adults Based on Estimated Creatinine Clearance (CLcr) (2.1, 2.2) Estimated CLcr (ML\/Min) a Dose b Infusion Time Dosing Interval c."},{"key":"927_CR53","doi-asserted-by":"publisher","first-page":"00472","DOI":"10.1128\/AAC.00472-17","volume":"61","author":"JA Karlowsky","year":"2017","unstructured":"Karlowsky JA, et al. In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015. Antimicrob Agents Chemother. 2017;61:00472\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"927_CR54","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/antibiotics10081012","volume":"10","author":"C Mauri","year":"2021","unstructured":"Mauri C, Maraolo AE, Di Bella S, Luzzaro F, Principe L. The Revival of Aztreonam in Combination with Avibactam against Metallo-\u03b2-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases. Antibiotics. 2021;10:1012.","journal-title":"Antibiotics"},{"key":"927_CR55","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s40121-025-01202-6","volume":"14","author":"R Ferrer","year":"2025","unstructured":"Ferrer R, et al. Estimating the Value of Aztreonam-Avibactam in Treating Metallo-beta-Lactamase-Producing Enterobacterales Infections in Spain Using the STEDI AMR Value Framework. Infect Dis Ther. 2025;14:2071\u201392.","journal-title":"Infect Dis Ther"},{"key":"927_CR56","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3390\/antibiotics13080766","volume":"13","author":"DW Wong","year":"2024","unstructured":"Wong DW. Practical Application of Aztreonam-Avibactam as a Treatment Strategy for Ambler Class B Metallo-\u03b2-Lactamase Producing Enterobacteriaceae. Antibiotics. 2024;13:766.","journal-title":"Antibiotics"},{"key":"927_CR57","doi-asserted-by":"publisher","first-page":"e0154823","DOI":"10.1128\/aac.01548-23","volume":"68","author":"C Le Terrier","year":"2024","unstructured":"Le Terrier C, Nordmann P, Buchs C, Poirel L. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum \u03b2-lactamases. Antimicrob Agents Chemother. 2024;68:e0154823.","journal-title":"Antimicrob Agents Chemother"},{"key":"927_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107425","volume":"65","author":"X Xiang","year":"2025","unstructured":"Xiang X, et al. Multiple mechanisms mediate aztreonam-avibactam resistance in Klebsiella pneumoniae: Driven by KPC-2 and OmpK36 mutations. Int J Antimicrob Agents. 2025;65:107425.","journal-title":"Int J Antimicrob Agents"},{"key":"927_CR59","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00148-22","volume":"10","author":"E Eger","year":"2022","unstructured":"Eger E, et al. Extensively Drug-Resistant Klebsiella pneumoniae Counteracts Fitness and Virulence Costs That Accompanied Ceftazidime-Avibactam Resistance Acquisition. Microbiol Spectr. 2022;10:e001482.","journal-title":"Microbiol Spectr"},{"key":"927_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107256","volume":"64","author":"C Tellapragada","year":"2024","unstructured":"Tellapragada C, et al. Resistance to aztreonam-avibactam among clinical isolates of Escherichia coli is primarily mediated by altered penicillin-binding protein 3 and impermeability. Int J Antimicrob Agents. 2024;64:107256.","journal-title":"Int J Antimicrob Agents"},{"key":"927_CR61","doi-asserted-by":"publisher","first-page":"e01615","DOI":"10.1128\/AAC.01659-20","volume":"64","author":"M Sadek","year":"2020","unstructured":"Sadek M, Juhas M, Poirel L, Nordmann P. Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-\u03b2-Lactamase-Producing Escherichia coli Isolates. Antimicrob Agents Chemother. 2020;64:e01615\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"927_CR62","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00588-23","volume":"61","author":"C Viguier","year":"2023","unstructured":"Viguier C, et al. Rapid Aztreonam\/Avibactam NP test for detection of aztreonam\/avibactam susceptibility\/resistance in Enterobacterales. J Clin Microbiol. 2023;61:e0058823.","journal-title":"J Clin Microbiol"},{"key":"927_CR63","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/IDR.S246174","volume":"14","author":"X Tan","year":"2021","unstructured":"Tan X, et al. Therapeutic options for metallo-\u03b2-lactamaseproducing enterobacterales. Infect Drug Resistance. 2021;14:125\u201342. https:\/\/doi.org\/10.2147\/IDR.S246174.","journal-title":"Infect Drug Resistance"},{"key":"927_CR64","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1093\/jac\/dkac279","volume":"77","author":"M Graham","year":"2022","unstructured":"Graham M, et al. Establishment of RCPA national guidelines for selective reporting of antimicrobials: processes, challenges and measuring the impact. J Antimicrob Chemother. 2022;77:3064\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"927_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19542-2","volume":"24","author":"K Zay Ya","year":"2024","unstructured":"Zay Ya K, Lambiris MJ, Levine GA, Tediosi F, Fink G. Coverage of policies to improve antimicrobial stewardship in human medicine in low and middle income countries: results from the Global Survey of Experts on Antimicrobial Resistance. BMC Public Health. 2024;24:2297.","journal-title":"BMC Public Health"},{"key":"927_CR66","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10096-024-05027-y","volume":"44","author":"F Pennisi","year":"2025","unstructured":"Pennisi F, Pinto A, Ricciardi GE, Signorelli C, Gianfredi V. Artificial intelligence in antimicrobial stewardship: a systematic review and meta-analysis of predictive performance and diagnostic accuracy. Eur J Clin Microbiol Infect Dis. 2025;44:463\u2013513.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"927_CR67","doi-asserted-by":"publisher","first-page":"106776","DOI":"10.1016\/j.ijantimicag.2023.106776","volume":"61","author":"DM Livermore","year":"2023","unstructured":"Livermore DM, Mushtaq S, Vickers A, Woodford N. Activity of aztreonam\/avibactam against metallo-\u03b2-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 \u03b2-lactamase in Escherichia coli. Int J Antimicrob Agents. 2023;61:106776.","journal-title":"Int J Antimicrob Agents"},{"key":"927_CR68","doi-asserted-by":"publisher","first-page":"1043112","DOI":"10.3389\/fcimb.2022.1000445","volume":"12","author":"EJ Kim","year":"2023","unstructured":"Kim EJ, et al. Development of a novel loop-mediated isothermal amplification assay for \u00df-lactamase gene identification using clinical isolates of Gram-negative bacteria. Front Cell Infect Microbiol. 2023;12:1043112.","journal-title":"Front Cell Infect Microbiol"},{"key":"927_CR69","doi-asserted-by":"publisher","unstructured":"Helsens N, Sadek M, Le Terrier C, Poirel L, Nordmann P. Reduced susceptibility to aztreonam-avibactam conferred by acquired AmpC-type \u03b2-lactamases in PBP3-modified Escherichia coli. Eur J Clin Microbiol Infect Diseases (2024) https:\/\/doi.org\/10.1007\/s10096-024-04769-z.","DOI":"10.1007\/s10096-024-04769-z"},{"key":"927_CR70","unstructured":"New Partnership to Improve Access to New Antibiotics in Low-and Middle-Income Countries to Boost Efforts to Combat TB and AMR. www.gardp.org."}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00927-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T22:03:03Z","timestamp":1782684183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00927-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["927"],"URL":"https:\/\/doi.org\/10.1038\/s41429-026-00927-x","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}